What a 26% rise in coupling-reagent prices does to a 15 mg vial
Follow the resin, not the catalogue.
January 2026 — Vol. 3, No. 1
Page 2 of 4 of this archive, newest first.
Also filed — page 2
the rolling newsroom, January 2026VendorInvestigate result on a Zhuhai retatrutide lot lands 1.8 points below the supplier’s figure
A reminder that a purity figure is the output of a method, and that methods differ.
Italy health authority warns on falsified semaglutide pens
Reported from the analysis, not from a warning notice.
SURMOUNT-4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The United Kingdom declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
What changed at SGN in January, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Brazil caps exenatide prescribing to 17 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Inspectors cite the relabeller trading as Vantris Bio over sterility assurance
The observation that closes a facility is rarely the dramatic one.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Singapore health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
BCH declines, for the 14th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What the new South Africa guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Shanghai: 24 posters, one theme
Reported from the sessions, and from the two hours afterwards.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 8 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of Halvard & Pike Apothecary of Portland, Maine
A proper account of an operation that existed, and of what closing it cost.
A supplier suspends shipping to Ireland after 5 consecutive customs detentions
The route did not close because of a rule about peptides.
The 25-day notice: how a compounding wind-down works in Denmark
The document is four pages. Three of them are about dates.
The consolidator trading as Meridian Freight Partners closes after 21 years
A proper account of an operation that existed, and of what closing it cost.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
What a 17% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
Portugal caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Shanghai export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Singapore declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Halvard & Pike Apothecary of Portland, Maine closes after 4 years
A proper account of an operation that existed, and of what closing it cost.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.